Insider Selling: NIOX Group (LON:NIOX) Insider Sells 34,219 Shares of Stock

NIOX Group Plc (LON:NIOX) insider Sarah Duncan sold 34,219 shares of the business’s stock in a transaction on Thursday, May 28th. The stock was sold at an average price of GBX 58, for a total transaction of £19,847.02.

Sarah Duncan also recently made the following trade(s):

• On Thursday, May 28th, Sarah Duncan bought 34,139 shares of NIOX Group stock. The shares were purchased at an average cost of GBX 58 per share, for a total transaction of £19,800.62.
• On Friday, May 29th, Sarah Duncan bought 34,127 shares of NIOX Group stock. The shares were purchased at an average cost of GBX 59 per share, for a total transaction of £20,134.93.
• On Friday, May 29th, Sarah Duncan sold 33,916 shares of NIOX Group stock. The stock was sold at an average price of GBX 59, for a total transaction of £20,010.44.
• On Thursday, April 16th, Sarah Duncan sold 164,612 shares of NIOX Group stock. The stock was sold at an average price of GBX 56, for a total transaction of £92,182.72.

NIOX Group Stock Up 0.2%

Shares of LON NIOX traded up GBX 0.14 during trading on Friday, reaching GBX 58.54. 268,082 shares of the stock were exchanged, compared to its average volume of 836,268. The business’s 50-day moving average price is GBX 60.09 and its 200 day moving average price is GBX 64.66. NIOX Group Plc has a twelve month low of GBX 53.84 and a twelve month high of GBX 77.60. The company has a quick ratio of 1.94, a current ratio of 3.81 and a debt-to-equity ratio of 1.36. The company has a market capitalization of £246.11 million, a price-to-earnings ratio of 35.69 and a beta of 0.92.

NIOX Group (LON:NIOX) last posted its earnings results on Tuesday, March 24th. The company reported GBX 4.03 EPS for the quarter. NIOX Group had a net margin of 14.37% and a return on equity of 10.14%. As a group, equities analysts forecast that NIOX Group Plc will post 1.1658256 EPS for the current fiscal year.

About NIOX Group

NIOX Group plc is a medical technology company focused on improving the lives of millions of people suffering from respiratory health issues globally. NIOX develops and markets innovative, non-invasive diagnostic products for chronic airway diseases, primarily asthma and COPD. Its lead product, NIOX VERO®, enables the accurate measurement of fractional exhaled nitric oxide (FeNO), an established biomarker for airway inflammation, supporting better diagnosis, monitoring and management of asthma and COPD in clinical and research settings.

Headquartered in the UK and listed on the London Stock Exchange (ticker: NIOX), the company operates internationally, serving healthcare professionals in over 50 countries.